Loading stock…

Omnicell, Inc. (OMCL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Omnicell, Inc.

OMCLMarket cap $1.61BPrice $35.2

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Builds robotic medication dispensing systems and software that automate drug management inside hospitals and pharmacies. Over 3,500 hospitals rely on its machines to cut medication errors that kill more Americans yearly than car crashes.

In Bastion Portfolios?

52W Return+18%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-3%2

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+4%3

Rev CAGR (5y)+5%4

Earnings Forecast

EPS Growth Y+1+5084%10

EPS Growth Y+2-3%3

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin4%2

Net Income Margin3%3

Free Cash Flow Margin11%6

Debt

Net Debt/EBITDA-1.010

Efficiency

ROE3%2

ROA2%4

Earnings Stability33

GEAR+WEAK19

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)145

P/BV1.29

EV Multiples

EV/EBITDA Fwd87

EV/EBIT Fwd127

Yield

Free Cash Flow Yield8.7%9

Dividend Yieldna–

Momentum

Short term

1 month return+4%9

3 month return-22%1

YTD return-22%2

Mid term

Price vs 52wHigh64%3

1 year return+12%6

Long term

3 year return-19%2

5 year return-78%1

Risk Shield

Price Risk

Beta0.95

Volatility50%3

Free Cash Flow

Free Cash Flow Margin11%6

Free Cash Flow Yield8.7%9

Quality

ROCE3%2

Earnings Stability33

Net Debt/EBITDA-1.010

02Growth

Is it actually growing, and how fast?

OMCLOmnicell

Revenue FY25$1.2B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+5084%10

EPS growth, FY27E-3%3

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 3% in year 2.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK17 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return-22%1

YTD return-22%2

MID & LONG-TERM▾SCORE

% of 52-week high64%3

1-year return+12%6

3-year return-19%2

5-year return-78%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+4%).

WATCH

It's up 12% over the past year, but 36% below its 52-week high. That is right in line with the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -78% over five), behind 80% of the market.

The stock is underperforming over three months (-22%) and so far this year (-22%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Omnicell, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

OMCLOmnicell

Revenue FY25$1.2B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-3%2

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+5084%10

EPS growth, FY27E-3%3

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

After shrinking over the last 3 years, revenue is set to grow 4%/yr from here.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 4%/yr), so margins should widen. One year dips: EPS falls 3% in year 2.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue fell 3%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK17 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return-22%1

YTD return-22%2

MID & LONG-TERM▾SCORE

% of 52-week high64%3

1-year return+12%6

3-year return-19%2

5-year return-78%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+4%).

WATCH

It's up 12% over the past year, but 36% below its 52-week high. That is right in line with the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -78% over five), behind 80% of the market.

The stock is underperforming over three months (-22%) and so far this year (-22%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Omnicell, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community